Lupin receives tentative approval from U.S. FDA for Letermovir tablets
The generic equivalent of Prevymis, will be manufactured at Lupin’s Nagpur facility in India Lupin has announced that it has…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
Bionova Scientific announces $100 million investment in new Plasmid DNA facility
Bionova Scientific aims to offer pDNA development services and production of research grade and high quality pDNA Bionova…
Moderna receives U.S. FDA approval for RSV vaccine mRESVIA(R)
mRESVIA is Moderna's second approved product and reportedly the only RSV vaccine available in single-dose pre-filled syringes …
Lupin launches Doxycycline for Injection USP in the United States
Generic equivalent of Vibramycin for Injection, the drug is indicated to reduce the development of drug-resistant bacteria and…
Amylyx’s efforts to explore other indications for Relyvrio seems to be bearing fruit: GlobalData
Amylyx explores new indications for Relyvrio after ALS trail setback, with early success in Wolfram syndrome and other…
TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs.…
First and only EGFR inhibitor and targeted treatment to show benefit in stage III setting, extending progression-free survival…
Puma Biotechnology announces presentation of findings from a phase II study of alisertib in…
Ongoing biomarker analysis may help clarify which patients could benefit most from alisertib Puma Biotechnology, announced the…
Regulatory measures for cybersecurity in India’s pharmaceutical industry
By Sidharrth Shankar, Partner, JSA Advocates and Solicitors
Demystifying pharma science: Batch v/s continuous manufacturing – choosing the right approach
By Indu Bhushan, CEO & Director, STEERLife
IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space: GlobalData
According to the results, the use of MOR-202 (felzartamab) demonstrated a deep and durable reduction in proteinuria in patients…
DoP orders pharma cos to comply to self-declaration under UPCMP 2024
Executive heads of companies must sign and submit the declarations by June 30
Biogen receives EC approval for QALSODY to treat rare genetic form of ALS
EC granted marketing authorisation under exceptional circumstances and maintained orphan designation for QALSODY (tofersen) for…
Parse Biosciences launches data analysis platform Trailmaker
New cloud platform facilitates streamlined, end-to-end analysis of single cell data
iBRIC organises 2nd THSTI advanced course in vaccinology
This course aims to provide a comprehensive overview of the concepts and steps involved in the design, development and…
JJP Biologics to execute in-human clinical trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)
JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential…
Neurology remains key therapeutic area for Japan pharma majors: GlobalData
According to GlobalData, the number of diagnosed prevalent cases of Alzheimer’s disease across major markets in APAC is expected…
Alembic announces USFDA approval for Sacubitril and Valsartan tablets
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in…
Tris Pharma receives USFDA approval for ONYDA XR, a liquid non-stimulant ADHD medication
ONYDA XR is indicated for the treatment of ADHD as monotherapy or as adjunctive therapy to approved CNS stimulant medications in…
Merck KGaA announces its largest investment in Asia
Once completed, the investment aims to create as many as 300 new jobs and continue to grow and support global demand for critical…
FDA grants priority review to Genentech’s Inavolisib
The priority review is granted for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation